AZ trials diabetes drug Forxiga in kidney disease, heart failure
AstraZeneca has launched two new trials with its SGLT-2 inhibitor Forxiga (dapagliflozin) exploring its potential beyond the drug’s approved diabetes indication.
Read More
Tag: SGLT-2 inhibitor
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
